The IntegriCell Platform Will Deliver
High-Quality Cryopreservation Services for Cell-Based
Therapies
NASHVILLE, Tenn., Oct. 7, 2024
/PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or
"the Company"), a global leader in supply chain solutions for the
life sciences, today announced the launch of its IntegriCell™
cryopreservation services solution provided by Cryoport Systems
with the opening of its new facility located at Cryoport's
integrated supply chain campus in Houston, Texas. This new state-of-the-art
facility is dedicated to the standardized cryopreservation of
leukapheresis material, seamlessly integrating this service with
Cryoport's end-to-end global temperature-controlled supply chain
platform to support the development and commercialization of
cell-based therapies.
IntegriCell is a standardized bioprocessing, cryopreservation,
and distribution solution for the global cell therapy market. The
platform is designed to enhance cell therapy manufacturing
efficiency and flexibility, ensuring safety, quality and product
stability to support the production of these lifesaving treatments.
The Cryoport Systems' Houston site
also supports GMP-compliant biostorage and a full suite of
bioservices, including secondary packaging, labeling, kit
production and Cryoport's extensive array of logistics
capabilities. A Grand Opening event will take place onsite on
October 22nd at
1:00 PM CT following the Association
for the Advancement of Blood & Biotherapies Annual Meeting in
Houston, Texas.
"Our new facility expands our presence on our Houston campus and is an important milestone
in our commitment to providing integrated supply chain solutions to
support the advancement of cell and gene therapies," said
Jerrell Shelton, CEO of Cryoport.
"We believe the IntegriCell platform will provide medical
researchers, clinical developers, and regenerative therapy
manufacturers with the industry's first complete solution for
delivering optimized cellular starting materials using systematic
bioprocessing and cryopreservation protocols. This will accelerate
the delivery of these cell therapy treatments to patients and open
up additional revenue streams for our company with new and existing
customers."
The Cryoport Global Supply Chain Center campus in Houston houses cutting-edge equipment systems
and processes to ensure GMP compliant supply chain solutions
including cryopreservation services, logistics, biostorage and
fulfilment for commercialized cell and gene therapies. The
Houston campus incorporates all of
Cryoport's business units, including Cryoport Systems, CRYOGENE,
CRYOPDP, and MVE Biological Solutions, providing an unmatched range
of services from a central location.
About Cryoport, Inc.
Cryoport, Inc. (Nasdaq: CYRX), is
a global leader in supply chain solutions for the Life Sciences
with an emphasis on cell & gene therapies. Cryoport enables
manufacturers, contract manufacturers (CDMO's), contract research
organizations (CRO's), developers, and researchers to carry out
their respective business with products and services that are
designed to derisk services and provide certainty. We provide a
broad array of supply chain solutions for the life sciences
industry. Through our platform of critical products and solutions
including advanced temperature-controlled packaging, informatics,
specialized bio-logistics services, bio-storage, bio-services, and
cryogenic systems, we are "Enabling the Future of Medicine™"
worldwide, through our innovative systems, compliant procedures,
and agile approach to superior supply chain management.
Our corporate headquarters, located in Nashville, Tennessee, is complemented by over
50 global locations in 17 countries, with key sites in the United States, United Kingdom, France, the
Netherlands, Belgium,
Portugal, Germany, Japan, Australia, India, and China.
For more information, visit www.cryoportinc.com or follow via
LinkedIn at https://www.linkedin.com/company/cryoportinc or
@cryoport on X, formerly known as Twitter at
www.twitter.com/cryoport for live updates.
Forward-Looking Statements
Statements in this press
release which are not purely historical, including statements
regarding Cryoport's intentions, hopes, beliefs, expectations,
representations, projections, plans or predictions of the future,
are forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, but are not limited to, those related to
Cryoport's expectations about future benefits of the IntegriCell
platform to support the development and commercialization of cell
and gene therapies, including the potential impact on future
revenue and revenue streams. It is important to note that
Cryoport's actual results could differ materially from those in any
such forward-looking statements. Factors that could cause actual
results to differ materially include, but are not limited to, risks
and uncertainties associated with the effect of changing economic
and geopolitical conditions, supply chain constraints, inflationary
pressures, the effects of foreign currency fluctuations, trends in
the products markets, variations in Cryoport's cash flow, market
acceptance risks, and technical development risks. Cryoport's
business could be affected by other factors discussed in Cryoport's
SEC reports, including in the "Risk Factors" section of its most
recently filed periodic reports on Form 10-K and Form 10-Q, as well
as in its subsequent filings with the SEC. The forward-looking
statements contained in this press release speak only as of the
date hereof and Cryoport cautions investors not to place undue
reliance on these forward-looking statements. Except as required by
law, Cryoport disclaims any obligation, and does not undertake to
update or revise any forward-looking statements in this press
release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cryoport-launches-its-integricell-cryopreservation-solution-with-opening-of-new-facility-at-its-houston-campus-302268614.html
SOURCE Cryoport, Inc.